Drug
5ARI
5ARI is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completed
5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression
NCT02876757
completed
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
NCT01323998
completed
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
NCT01376258
completed
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
NCT01386983
Clinical Trials (4)
Showing 4 of 4 trials
NCT02876757
5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression
NCT01323998
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
NCT01376258
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
NCT01386983
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4